TY - JOUR
T1 - Effect of a new de-N-acetyl-lysoglycosphingolipid on some tumour models
AU - Tubaro, Ezio
AU - Borelli, Giorgio P.
AU - Belogi, Luisella
AU - Cavallo, Giovanni
AU - Santoni, Angela
AU - Mainiero, Fabrizio
PY - 1995/12/29
Y1 - 1995/12/29
N2 - A new de-N-acetylated glycosphingolipid termed WILD20, a breakdown product of GM1 obtained through alkaline hydrolysis, and characterized by nuclear magnetic resonance, mass spectrometry and elementary analysis, was found to inhibit phospholipase A2 via phosphokinase C translocation blockade. The substance inhibited various tumour cell lines in vitro, in synergy with doxorubicin and cisplatin. In vivo, it showed an antitumoral effect when both the tumour cells and WILD20 were injected at the same site (peritoneal cavity). Tumour cells, incubated with WILD20, showed a dose-dependent decrease of oncogenicity without impairment of viability. WILD20 also down-regulated tumour cell adherence to laminin and fibronectin. When peritumorally administered, WILD20 impaired tumour growth and potentiated the peritumoral effects of recombinant interleukin 2. The results obtained merit exploration of the therapeutical possibilities of this agent in human cancer patients.
AB - A new de-N-acetylated glycosphingolipid termed WILD20, a breakdown product of GM1 obtained through alkaline hydrolysis, and characterized by nuclear magnetic resonance, mass spectrometry and elementary analysis, was found to inhibit phospholipase A2 via phosphokinase C translocation blockade. The substance inhibited various tumour cell lines in vitro, in synergy with doxorubicin and cisplatin. In vivo, it showed an antitumoral effect when both the tumour cells and WILD20 were injected at the same site (peritoneal cavity). Tumour cells, incubated with WILD20, showed a dose-dependent decrease of oncogenicity without impairment of viability. WILD20 also down-regulated tumour cell adherence to laminin and fibronectin. When peritumorally administered, WILD20 impaired tumour growth and potentiated the peritumoral effects of recombinant interleukin 2. The results obtained merit exploration of the therapeutical possibilities of this agent in human cancer patients.
KW - Adhesion
KW - Glycosphingolipid
KW - Peritumoral
KW - Recombinant interleukin-2
KW - Tumor
UR - http://www.scopus.com/inward/record.url?scp=0029591484&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0029591484&partnerID=8YFLogxK
U2 - 10.1016/0014-2999(95)00583-8
DO - 10.1016/0014-2999(95)00583-8
M3 - Article
C2 - 8750718
AN - SCOPUS:0029591484
VL - 294
SP - 555
EP - 563
JO - European Journal of Pharmacology
JF - European Journal of Pharmacology
SN - 0014-2999
IS - 2-3
ER -